Pey-Jey Peng

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

1. Introduction The worldwide incidence of hepatocellular carcinoma (HCC) is increasing, and the mortality rate is high [1]. Treatment choice and prognosis for HCC patients are generally determined using the Barcelona Clinical Liver Cancer (BCLC) staging system based on tumor burden, tumor staging, and liver function. Additionally, other prognostic scores such as the ALBI and ART scores have emerged, showing potential relevance in TACE patients [2].